These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy. Saijo N Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125 [No Abstract] [Full Text] [Related]
46. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Steins MB; Reinmuth N; Bischoff H; Kindermann M; Thomas M Onkologie; 2010; 33(12):704-9. PubMed ID: 21124044 [TBL] [Abstract][Full Text] [Related]
47. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
48. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. Chang GC; Yang TY; Chen KC; Yin MC; Wang RC; Lin YC J Clin Oncol; 2004 Nov; 22(22):4646-8. PubMed ID: 15542815 [No Abstract] [Full Text] [Related]
49. Pressure sore-like ulcers on acneiform papules caused by EGFR inhibitors. Miyawaki S; Tohyama M; Irifune K; Ito R; Sayama K Int Wound J; 2014 Oct; 11(5):569-70. PubMed ID: 23517492 [No Abstract] [Full Text] [Related]
50. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer. Tang C; Gao H; Li X; Liu Y; Li J; Qin H; Wang W; Qu L; An J; Yang S; Liu X J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995 [TBL] [Abstract][Full Text] [Related]
51. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Pallis AG; Mavroudis D; Androulakis N; Souglakos J; Kouroussis C; Bozionelou V; Vlachonikolis IG; Georgoulias V Lung Cancer; 2003 Jun; 40(3):301-7. PubMed ID: 12781429 [TBL] [Abstract][Full Text] [Related]
52. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Pao W; Miller VA; Kris MG Semin Cancer Biol; 2004 Feb; 14(1):33-40. PubMed ID: 14757534 [TBL] [Abstract][Full Text] [Related]
53. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073 [TBL] [Abstract][Full Text] [Related]
54. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Marquez-Medina D; Popat S Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834 [TBL] [Abstract][Full Text] [Related]
55. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. Ready N Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534 [TBL] [Abstract][Full Text] [Related]
56. BAD: a good therapeutic target? Motoyama AB; Hynes NE Breast Cancer Res; 2003; 5(1):27-30. PubMed ID: 12559042 [TBL] [Abstract][Full Text] [Related]
57. [Molecular diagnostics in lung carcinoma for therapy stratification]. Heukamp LC; Büttner R Pathologe; 2010 Feb; 31(1):22-8. PubMed ID: 19997736 [TBL] [Abstract][Full Text] [Related]
58. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264 [TBL] [Abstract][Full Text] [Related]
59. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278 [TBL] [Abstract][Full Text] [Related]
60. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]